Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" [1] Core Views - The company reported strong performance in H1 2025, with revenue reaching 20.64% year-on-year growth and a significant increase in net profit by 101.92% [4][5] - The TIDES business segment showed robust growth, with revenue increasing by 141.6% year-on-year, indicating strong demand and expansion potential [5] - The company has raised its revenue guidance for 2025 from 41.5-43 billion to 42.5-43.5 billion, reflecting positive market conditions and order growth [4] Financial Performance Summary - In H1 2025, the company achieved revenue of 20.799 billion, a 20.64% increase year-on-year, and a net profit of 8.561 billion, up 101.92% [4] - For Q2 2025, revenue was 11.145 billion, showing a 20.37% year-on-year increase and a 15.43% quarter-on-quarter increase [4] - The adjusted Non-IFRS net profit for H1 2025 was 6.31 billion, reflecting a 44.4% year-on-year growth [4] Business Segment Performance - The chemical business segment generated revenue of 16.3 billion in H1 2025, marking a 33.5% increase year-on-year [5] - The TIDES business segment's revenue was approximately 5.03 billion in H1 2025, with a 48.8% increase in orders by the end of June 2025 [5] - The clinical business segment reported a slight decline in revenue, but the overall performance remains stable with a focus on expanding new molecular types [6] Financial Projections - The company expects net profit for 2025-2027 to be 13.407 billion, 15.127 billion, and 17.939 billion respectively, with EPS projected at 4.67, 5.27, and 6.25 [4][8] - The current price-to-earnings ratio (PE) is projected at 21.2, 18.8, and 15.8 for the years 2025, 2026, and 2027 respectively [4][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's neuro-related business is experiencing rapid growth, and its innovative pipeline is gradually being realized. The performance drivers are clear, and the company is expected to maintain its profit forecast [4][5] Financial Performance Summary - In H1 2025, the company achieved revenue of 3.01 billion yuan (up 8.93% year-on-year, up 2.59% quarter-on-quarter) and a net profit attributable to shareholders of 700 million yuan (up 11.38% year-on-year, up 36.11% quarter-on-quarter). The gross margin was 75.24% (up 2.74 percentage points), and the net margin was 23.26% (up 0.59 percentage points) [3][4] - For Q2 2025, the company reported revenue of 1.499 billion yuan (up 6.64% year-on-year, down 0.77% quarter-on-quarter) and a net profit of 400 million yuan (up 9.94% year-on-year, up 32.95% quarter-on-quarter) [3] Business Segment Performance - In H1 2025, the revenue breakdown by business segment was as follows: Anesthesia products at 1.634 billion yuan (up 7.32%), psychiatric products at 621 million yuan (up 4.29%), neuro products at 166 million yuan (up 107.33%), raw materials at 90 million yuan (down 6.17%), and commercial pharmaceuticals at 394 million yuan (up 9.80%) [4] Future Profit Forecast - The company is expected to achieve net profits attributable to shareholders of 1.294 billion yuan, 1.495 billion yuan, and 1.746 billion yuan for the years 2025, 2026, and 2027, respectively. The expected EPS for these years is 1.27 yuan, 1.47 yuan, and 1.72 yuan per share, with corresponding P/E ratios of 17.5, 15.2, and 13.0 times [4][8] R&D and Innovation Pipeline - The company is focusing on product differentiation and has 17 innovative drug projects in development. It has completed one Phase III clinical trial and two Phase II trials, with several other projects at various stages of clinical research [5]

宏观经济点评 2025 年 07 月 31 日 美联储内部分歧加大，降息或尚需时日 宏观研究团队 ——7 月 FOMC 会议点评 hening@kysec.cn 证书编号：S0790522110002 何宁（分析师） 潘纬桢（分析师） panweizhen@kysec.cn 证书编号：S0790122110044 事件：美联储于北京时间 7 月 31 日凌晨 2 点发布 7 月 FOMC 会议声明，宣布保 持利率水平不变。 声明及发布会要点 1. 美联储在此次会议上宣布维持利率水平在 4.25%-4.5%区间。缩表方面，将继 续按照 3 月 FOMC 会议上的原定计划执行。 2. 再次维持利率水平不变，认为经济不确定性仍高，出现 2 张反对票。在声明 中，美联储的措辞同 6 月份相比略有变化，认为虽然净出口的波动影响了经济数 据，但上半年美国经济活动增长有所放缓。就业与通胀方面，与 6 月表述基本相 同。但美联储认为美国经济前景的不确定性依旧高涨。此外，本次会议中出现两 票反对，鲍曼以及沃勒认为本次会议中应该降息 25bp，与其前期表态一致，但 凸显出美联储内部的分歧进一步显性化。 3. 发布会上，鲍威尔表态 ...

Economic Outlook - The Politburo meeting on July 30 emphasized the strong vitality and resilience of the economy in the first half of the year, while urging caution for the second half[2] - The focus for the "14th Five-Year Plan" is expected to be on actively expanding domestic demand and responding to external changes, particularly in manufacturing investment and service consumption[2][3] Policy Direction - The macro policy will continue to exert force and adapt as necessary, with a key emphasis on effectively releasing policy effects and potential for domestic demand[3][4] - Fiscal policy will prioritize the implementation of existing policies, focusing on quality rather than quantity, to enhance the fiscal multiplier effect[4] Fiscal and Monetary Measures - The issuance of special bonds and ultra-long-term treasury bonds is expected to maintain a certain intensity in Q3, with a focus on consumption and investment[4] - There is a higher probability of interest rate cuts and reserve requirement ratio reductions in Q4 compared to Q3, given the economic pressures[5] Domestic Demand and Investment - The meeting highlighted the importance of effectively releasing domestic demand potential, with a focus on service consumption growth and investment in urban renewal projects[5][6] - Urban development is shifting from expansion to quality improvement, emphasizing the renovation of existing structures and infrastructure upgrades[6] Market and Trade Stability - The meeting underscored the need to stabilize foreign trade and foreign investment, with policies aimed at maintaining a solid foundation in these areas[6] - There is a continued emphasis on stabilizing the stock market to attract long-term capital and maintain market momentum[6]

Core Insights - The report highlights a positive outlook for the AI computing industry, driven by significant investments from major overseas companies, which is expected to boost the demand for related technologies and services [25][27][33] - The introduction of a national childcare subsidy program in China is anticipated to stimulate demand in the dairy sector, particularly in infant formula, as it aims to increase birth rates [43][44][45] - The report emphasizes the growth potential in the communication sector, particularly for Corning, which reported strong Q2 earnings and is expected to benefit from the increasing demand for AI-related technologies [24][25][26] Industry Analysis Communication Sector - Corning's Q2 2025 revenue reached $4.05 billion, a 12% year-on-year increase, with a notable 41% growth in its optical communications segment [24][25] - The company's "Scale-up" strategy is projected to significantly enhance its sales and profit margins by 2026, with expectations of a $10 billion market opportunity in data center interconnects by 2030 [26][27] Dairy Sector - The national childcare subsidy program is set to provide annual cash benefits of 3,600 yuan per child, which is expected to positively impact birth rates and subsequently increase demand for infant formula [43][44] - The report anticipates a recovery in the demand for infant formula in 2025, driven by the subsidy and a favorable demographic shift [45][46] AI Computing Industry - The integration of AI technologies is expected to create substantial market opportunities, particularly through platforms like NVIDIA's Omniverse, which facilitates collaboration and simulation across various industries [29][30][31] - The report identifies several investment opportunities within the AI computing supply chain, including optical modules and liquid cooling technologies, which are poised for growth as AI applications expand [27][33] Agricultural Sector - Haida Group reported a 12.5% increase in revenue for H1 2025, driven by strong sales in its feed business, particularly in the pig and poultry segments [60][61] - The company is also expanding its international market presence, with a 40% year-on-year increase in overseas feed sales [61][62] Real Estate and Property Management - South Property's diversified service model is expected to enhance profitability, with a projected net profit of 168 million yuan for 2025 [54][55] - The company is leveraging technology, such as cleaning robots, to improve service efficiency and reduce costs [58][59]

行 业 研 究 康宁 Q2 业绩表现亮眼，Scale-up 打开光通信成长空 2025 年 07 月 30 日 投资评级：看好（维持） ——行业点评报告 -17% 0% 17% 34% 50% 67% 2024-07 2024-11 2025-03 通信 沪深300 数据来源：聚源 相关研究报告 《Celestica 上调业绩指引，看好光通 信、液冷等板块估值提升—行业点评 报告》-2025.7.29 《谷歌上调资本开支，Qwen3 模型迎 更新，看好全球 AI 共振—行业周报》 -2025.7.27 "Scale-up"有望进一步打开光通信成长空间，重视光通信产业机遇 据康宁公告，2025Q2 企业网络销售额同比增长 81%，主要受"Scale-up"的推动， 超大规模客户正在打造更强的 AI 节点，新"Scale-up"机会（提升节点能力和 GPU 密度）预计是现有 20 亿美元业务的 2-3 倍规模；此外，在数据中心互联业 务方面，高带宽、低延迟连接需求上升，三家行业客户已采用新技术，预计到 2030 年成为 10 亿美元市场机会。整体来看，我们认为随着 AI 的不断迭代推进， 算力需求持续增加，算力通 ...

Investment Rating - The investment rating for the company is "Outperform" (Maintain) [1] Core Views - The company has maintained a strong growth momentum in H1 2025, with revenue reaching 10.74 billion yuan, a year-on-year increase of 36.4%. The net profit attributable to shareholders was 2.37 billion yuan, reflecting a growth of 37.2% [4][5] - The company plans to distribute a semi-annual dividend of 2.5 yuan per share for H1 2025, indicating confidence in its financial performance [4] - The growth in the electrolyte water segment remains robust, supporting the "Outperform" rating [4] Financial Performance Summary - In Q2 2025, the company reported a revenue of 5.89 billion yuan, a year-on-year increase of 34.1%, with net profits of 1.395 billion yuan, up 30.8% [4][5] - The company forecasts net profits for 2025-2027 to be 4.228 billion, 5.214 billion, and 5.745 billion yuan respectively, with corresponding EPS of 8.13, 10.03, and 11.05 yuan [4][9] - The current stock price corresponds to a P/E ratio of 35.3, 28.6, and 26.0 for 2025-2027 [4][9] Product Performance - The company's energy drink segment saw a revenue increase of 22.0% year-on-year, while the "Bup Shui La" product line experienced a remarkable growth of 213.7% due to rapid expansion in distribution and product offerings [5] - Other beverage products also performed well, with a year-on-year increase of 65.2% [5] Regional Performance - Revenue growth varied by region, with significant increases in Guangdong (19.4%), East China (34.0%), and North China (74.1%) [5] Profitability Metrics - The sales net profit margin slightly decreased by 0.6 percentage points to 23.7% in Q2 2025, attributed to high base effects [6] - The gross profit margin also saw a minor decline of 0.35 percentage points, although the decrease in raw material prices is expected to positively impact margins [6] New Product Development - The company has matured its new product development model, with established products growing at 15%-20% and new products like juice tea performing well [7]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The integration of Aisino's self-developed digital twin platform with NVIDIA Omniverse aims to empower the domestic manufacturing sector's transition from "manufacturing" to "intelligent manufacturing" [4] - NVIDIA Omniverse is an open platform designed for virtual collaboration and real-time simulation, with significant market potential, already adopted by over 700 companies and more than 70,000 individual creators [5] - The expansion of Omniverse usage is expected to create three industry opportunities, particularly benefiting the simulation market, computational power, delivery, and enterprise sectors [6][7] Summary by Sections Industry Trends - The report highlights the ongoing demand for computational power driven by sovereign AI and token consumption, indicating a sustained need for traditional AI targets [3] Company Focus - Aisino Technology is positioned to extend its delivery capabilities from large models and AI agents to AI platform delivery, with potential applications in various sectors including energy, finance, and manufacturing [7] - The report notes that Omniverse could enhance efficiency in downstream manufacturing, exemplified by Foxconn's production line layout cycle being shortened by 50% [8] Market Opportunities - The report emphasizes the potential for domestic simulation market demand to grow, with local alternatives like Songying Technology's ORCA system emerging to compete with Omniverse, offering localized and cost-effective solutions [8]

Investment Rating - The investment rating for the biotechnology industry is "Positive" (maintained) [1] Core Insights - The global stock of multiple sclerosis (MS) patients is significant, with the market size exceeding $20 billion, primarily focused on relapsing forms of MS (RMS) [6][9] - BTK inhibitors are expected to fill the treatment gap in primary progressive MS (PPMS) and non-relapsing secondary progressive MS (nrSPMS) [7][9] - The anticipated release of clinical data for BTK inhibitors in the second half of 2025 is expected to enhance the attractiveness of the sector [9] Summary by Sections 1. Multiple Sclerosis Overview - MS is an immune-mediated inflammatory demyelinating disease of the central nervous system, characterized by "spatial" and "temporal" multiplicity [5][27] - The global and Chinese stock of MS patients is projected to reach 3.71 million and 60,000 respectively by 2030, with a CAGR of approximately 2.7% and 2.1% from 2025 to 2030 [19][22] 2. Market Size and Product Landscape - The global MS market is approximately $20 billion, with a focus on RMS treatments [6][40] - Existing products include monoclonal antibodies and oral therapies, with CD20 monoclonal antibodies expected to account for over 60% of sales by 2024 [6][46] 3. BTK Inhibitors and Clinical Development - BTK inhibitors are positioned to address unmet needs in the treatment of PPMS and nrSPMS, with several candidates in late-stage clinical trials [7][51] - Tolebrutinib and Fenebrutinib are expected to release pivotal clinical data in the second half of 2025, which could significantly impact their market potential [8][51] 4. Investment Recommendations - The ongoing clinical developments and the large patient base present significant investment opportunities in companies like 诺诚健华, 翰森制药, 云顶新耀, 恒瑞医药, and 百济神州-U [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown rapid growth in its feed business, with significant performance in overseas markets. The revenue for H1 2025 reached 58.831 billion yuan, a year-on-year increase of 12.50%, while the net profit attributable to the parent company was 2.639 billion yuan, up 24.16% year-on-year. The second quarter of 2025 saw revenue of 32.2 billion yuan, a 14.00% increase year-on-year, and a net profit of 1.356 billion yuan, up 7.26% year-on-year. The company plans to distribute a cash dividend of 2 yuan for every 10 shares, totaling 333 million yuan. Due to the better-than-expected sales growth in pig and poultry feed, the profit forecasts for 2025-2027 have been slightly adjusted upwards [1][5]. Financial Performance Summary - In H1 2025, the feed business generated revenue of 47.139 billion yuan, a year-on-year increase of 14.02%, with a gross margin of 9.79%. The total feed sales reached 14.7 million tons, a growth of approximately 25% year-on-year. The external sales of poultry feed were 7.3 million tons, up 24% year-on-year, while pig feed external sales were 3.4 million tons, a 43% increase year-on-year. The external sales of aquatic feed reached 2.8 million tons, a 16% increase year-on-year. The overseas feed external sales increased by 40% year-on-year, indicating robust growth in established regions and active expansion into new areas [5][6]. Profitability and Growth Projections - The company's breeding business revenue for H1 2025 was 9.735 billion yuan, a year-on-year increase of 15.59%, with a gross margin of 20.26%. The animal health business generated revenue of 464 million yuan, a slight decrease of 0.35% year-on-year, while the seed business revenue was 770 million yuan, up 10% year-on-year. The company is focusing on building its breeding team capabilities and innovating its asset-light model, which has led to controllable risks and considerable profitability [6][9]. Earnings Forecast - The profit forecasts for the company are as follows: for 2025, 5.148 billion yuan; for 2026, 5.739 billion yuan; and for 2027, 6.172 billion yuan. The corresponding earnings per share (EPS) are projected to be 3.09 yuan, 3.45 yuan, and 3.71 yuan respectively. The current stock price corresponds to price-to-earnings (P/E) ratios of 17.7, 15.9, and 14.8 for the years 2025, 2026, and 2027 respectively [1][7].